particularly for therapy of atherogenic dyslipidemia. A Kontush is a Senior Research Investigator in and MJ Chapman is Director of the Dyslipoproteinemia and Atherosclerosis Research Unit (U.
AZD-1705 is under clinical development by AstraZeneca and currently in Phase I for Dyslipidemia. According to GlobalData, Phase I drugs for Dyslipidemia have a 68% phase transition success rate (PTSR) ...
Link Between Stroke and Heart Attack In many cases, stroke is caused by atherosclerosis, which is a narrowing and disease of the arteries that predisposes them to blockages. In the heart, coronary ...
ACC Online Courses offer the cardiovascular community a collection of resources and newly developed, evidence-based educational activities across topics such as lipid management, valvular heart ...
Dec. 11, 2024 — Scientists have made a significant breakthrough in understanding how 'bad' cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body. The ...
Evidence from epidemiologic studies indicates that the same factors that are associated with increased risk of coronary heart disease (CHD) in middle-aged people are relevant in older adults (i.e ...